We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.23B
AUM Growth
-$307M
Cap. Flow
+$10.8M
Cap. Flow %
0.88%
Top 10 Hldgs %
46.8%
Holding
78
New
13
Increased
11
Reduced
35
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.1M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$19.1M
3
TWST icon
Twist Bioscience
TWST
+$15.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$14.1M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$13.3M

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$40.7M
2
NKTR icon
Nektar Therapeutics
NKTR
+$33.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.8M
4
OMER icon
Omeros
OMER
+$14M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
CALL
DELISTED
TESARO, Inc.
TSRO
$93.1M 7.56%
1,253,300
+753,300
+151% +$36.2M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$74.3M 6.03%
1,751,699
-58,301
-3% -$2.32M
ANAB icon
3
AnaptysBio
ANAB
$1.54B
$70.5M 5.73%
1,105,557
-29,443
-3% -$2.19M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$66.8M 5.43%
900,000
-350,000
-28% -$16.8M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$59.4M 4.82%
4,502,498
+330,000
+8% +$5.06M
IFRX icon
6
InflaRx
IFRX
$243M
$53.7M 4.36%
1,475,140
+133,600
+10% +$4.11M
ARGX icon
7
argenx
ARGX
$55.2B
$43.2M 3.51%
450,000
+260,000
+137% +$23.1M
PRNB
8
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$40.4M 3.28%
1,474,362
-12,536
-0.8% -$323K
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$37.8M 3.07%
674,251
+14,251
+2% +$870K
DRNA
10
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$37.2M 3.02%
3,481,471
-75,198
-2% -$989K
KZR
11
DELISTED
Kezar Life Sciences
KZR
$33.6M 2.73%
142,291
-13,000
-8% -$3.18M
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$33.1M 2.69%
677,451
-22,549
-3% -$1.24M
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
$29.1M 2.37%
119,069
-2,181
-2% -$572K
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$343M
$28.8M 2.34%
1,945,659
+445,000
+30% +$7.39M
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$24M 1.95%
650,000
+390,000
+150% +$14.1M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$6.31B
$23.3M 1.9%
831,000
– –
TBPH icon
17
Theravance Biopharma
TBPH
$873M
$22.6M 1.84%
884,916
-215,084
-20% -$5.81M
TECX
18
Tectonic Therapeutic
TECX
$536M
$22.6M 1.84%
113,149
-11,250
-9% -$3.43M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.5B
$21.2M 1.72%
338,456
-11,544
-3% -$725K
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$19.5M 1.58%
361,351
-18,649
-5% -$1.13M
AXNX
21
DELISTED
Axonics, Inc. Common Stock
AXNX
$19.4M 1.58%
+1,285,828
New +$19.1M
GTHX
22
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$19M 1.55%
994,287
+353,806
+55% +$13.3M
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
$18.6M 1.51%
511,395
+11,395
+2% +$467K
ZLAB icon
24
Zai Lab
ZLAB
$2.07B
$18.3M 1.48%
787,426
-20,740
-3% -$385K
NKTR icon
25
Nektar Therapeutics
NKTR
$2.39B
$18M 1.46%
36,467
-54,866
-60% -$33.1M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Cormorant Asset Management held 78 positions worth $1.23B, down 20% from $1.54B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2018 filing shows 13 new, 11 increased, 35 reduced and 8 closed positions. Its largest new stake was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M. The largest sale was Autolus Therapeutics, an estimated $40.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2018 buy was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M.
  • Cormorant Asset Management added most to argenx in Q4 2018, an estimated $23.1M increase.
  • Cormorant Asset Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $33.1M.
  • Cormorant Asset Management fully exited Autolus Therapeutics in Q4 2018, selling an estimated $40.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.23B portfolio in Q4 2018.
  • Cormorant Asset Management opened 13 new positions and closed 8 in Q4 2018.
  • Cormorant Asset Management's portfolio value fell 20% quarter-over-quarter to $1.23B.

Based on Cormorant Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.